Rosetta Genomics BRAF Mutation Assay

Rosetta Genomics has launched a molecular test for BRAF mutation analysis to help personalize therapy for melanoma and colon cancer patients. The test uses competitive allele-specific TaqMan (CAST) PCR technology, which can detect as little as 0.5 percent mutated DNA in a large, normal DNA sample. BRAF mutations occur in up to 50 percent of malignant melanomas, and several US Food and Drug Administration-approved BRAF inhibitor therapies have been introduced to the market for use in patients with late-stage metastatic melanoma, Rosetta noted.